Healio

Collaboration to advance small activating RNA therapeutics for central nervous system

Please provide your email address to receive an email when new articles are posted on . A London-based biotech firm has announced a collaboration and licensing agreement with a Japanese pharmaceutical ...
MarketWatch

Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy

The MarketWatch News Department was not involved in the creation of this content. NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA ...
Becker's Hospital Review

Eli Lilly to develop drugs using saRNA platform in deal worth up to $1.25B

Eli Lilly signed a deal to use MiNA Therapeutics’ small activating RNA platform to develop drug candidates against up to five targets, the companies announced May 11. Under the deal, Eli Lilly will ...
Business Wire

MiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

LONDON--(BUSINESS WIRE)--MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, highlights preclinical research presented by academic partners at the annual meeting of the ...
Seeking Alpha

NS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous System

PARAMUS, N.J., April 4, 2024 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) – headquartered in Kyoto, Japan, entered into a ...
Business Wire

MiNA Therapeutics Presents New Pre-Clinical Data from Lead Sickle Cell Disease Program at the American Society of Hematology Annual Meeting

LONDON--(BUSINESS WIRE)--MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, today presented new pre-clinical data for its lead RNA activation program for the treatment ...

Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of ...